Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with ...

Shares of IO Biotech fell after the company said a cancer vaccine narrowly missed statistical significance on a Phase 3 study's primary endpoint. The stock was down 36%, to $1.15, late Monday ...

IO Biotech (NASDAQ:IOBT) stock gained 6.1% after revealing topline data from its pivotal Phase 3 trial evaluating Cylembio, ...

Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...